You are here: Industry Insights > Xoma

News List

XOMA Announces Heather L. Franklin Joins its Board of Directors firstwordpharma
August 11, 2021
XOMA Corporation (NASDAQ: XOMA) announced today Heather L. Franklin, President and Chief Executive Officer of Blaze Bioscience, Inc., has joined the Company's Board of Directors.
FDA Grants Pancreatic Cancer Treatment Orphan Drug Designation americanpharmaceuticalreview
July 29, 2021
XOMA Corporation announced NIS793 in combination with standard of care chemotherapy has been granted Orphan Drug Designation in pancreatic cancer by the U.S. FDA.
XOMA Earns $2M Takeda Milestone contractpharma
November 18, 2020
XOMA Corp. has earned a $2 million milestone payment from Takeda Pharmaceutical Company as the first patient has been dosed in its Phase 2 study to evaluate safety, tolerability, and efficacy of mezagitamab (TAK-079) in generalized myasthenia gravis.
Zydus, XOMA Enter IO Agreement contractpharma
March 10, 2020
To advance an IL-2-based immuno-oncology drug candidate that combines Zydus’ IL-2 with XOMA’s novel anti-IL-2 monoclonal antibody.
XOMA Announces Closing of Rights Offering firstwordpharma
December 22, 2019
The Rights Offering was made pursuant to the Company’s effective shelf registration statement on file with the Securities and Exchange Commission (the “SEC”) and a prospectus supplement and accompanying prospectus filed with the SEC on December 2, 2019.
Why Bay Area's XOMA Surged 700% in 2017 by Not Making Drugs biospace
January 29, 2018
It’s a common and accepted business practice for venture capital firms to invest in biotech companies, often running those companies until they get to a point where they can be acquired or partnered
Bay Area's XOMA Snags $240M Deal With Newly-Transformed Rezolute biospace
December 08, 2017
AntriaBio Announces Exclusive License Agreement for a Phase 2 Orphan Disease Therapy with XOMA Corporation and Name Change to Rezolute, Inc.